SRI-011381 hydrochloride
CAS No. 2070014-88-7
SRI-011381 hydrochloride ( —— )
产品货号. M23928 CAS No. 2070014-88-7
SRI-011381是一种新型TGF-β信号通路激动剂,用于治疗阿尔茨海默病。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥367 | 有现货 |
|
| 5MG | ¥582 | 有现货 |
|
| 10MG | ¥1007 | 有现货 |
|
| 25MG | ¥2027 | 有现货 |
|
| 50MG | ¥3283 | 有现货 |
|
| 100MG | ¥4455 | 有现货 |
|
| 200MG | ¥6273 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥471 | 有现货 |
|
生物学信息
-
产品名称SRI-011381 hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SRI-011381是一种新型TGF-β信号通路激动剂,用于治疗阿尔茨海默病。
-
产品描述SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.
-
体外实验SRI-011381 (10 μM) hydrochloride promotes the proliferation of mouse lung fibroblasts, and significantly increases TGF-β1, NALP3, collagen-1, and α-SMA expression.
-
体内实验SRI-011381 (30 mg/kg; i.p.; every 2 d; for 22 days) hydrochloride partially rescues the deficits in optic nerve and retina of YAPGFAP-CKO EAE mice. Animal Model:YAPGFAP-CKO mice bearing experimental autoimmune encephalomyelitis (EAE).Dosage:30 mg/kg Administration:Intraperitoneally injection; every 2 d; for 22 daysResult:Significantly inhibited inflammatory infiltration and relieved the loss of neurons in YAPGFAP-CKO EAE mice.
-
同义词——
-
通路TGF-beta/Smad
-
靶点TGFBR
-
受体TGF-β
-
研究领域——
-
适应症——
化学信息
-
CAS Number2070014-88-7
-
分子量365.94
-
分子式C20H32ClN3O
-
纯度>98% (HPLC)
-
溶解度DMSO: 10 mM
-
SMILESCl.O=C(NC1CCCCC1)N(CC1CCNCC1)Cc1ccccc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Benzyl urea derivatives for activating tgf-beta signaling. US 20160039756 A1. 2016. Feb
021-51111890
购物车()
sales@molnova.cn

